Randomized, Open Label, Phase 3 Trial Of Erlotinib Alone Or In Combination With Cp 751,871 In Patients With Advanced Non Small Cell Lung Cancer Of Non Adenocarcinoma Histology.

Trial Profile

Randomized, Open Label, Phase 3 Trial Of Erlotinib Alone Or In Combination With Cp 751,871 In Patients With Advanced Non Small Cell Lung Cancer Of Non Adenocarcinoma Histology.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 28 Jan 2016

At a glance

  • Drugs Figitumumab (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms ADVIGO
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 May 2012 Actual patient number changed from 582 to 583 as reported by ClinicalTrials.gov.
    • 16 Mar 2012 Planned End Date changed from 1 Jun 2012 to 1 Apr 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top